Eli Lilly Faces Zepbound Shortage, Impacting Weight Loss and Diabetes Patients

Despite previous assurances, Eli Lilly is unable to meet the demand for its weight loss drug Zepbound, causing significant disruptions for patients.

Eli Lilly reports a shortage of Zepbound, a weight loss drug, with limited availability expected to continue into June.
The shortage also affects Mounjaro, used for diabetes, as both drugs share the active ingredient tirzepatide.
Patients struggle to find available doses, with some facing the risk of having to restart treatment.
Lilly plans to open a new manufacturing facility in North Carolina by year's end to boost drug production.
The shortage has forced some doctors to switch patients to alternative medications, impacting treatment continuity.